UNSPSC 51172177: Oxyphencyclimine hydrochloride

This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formula C20H28N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GWO1432WOU, chemically known as 1,4,5,6-tetrahydro-1-methyl-2-pyrimidinylmethyl alpha-cyclohexyl-alpha-phenylglycolat but more generally known as oxyphencyclimine hydrochloride, which bears US NIH Compound Identifier 4642.

UNSPSC 51172177 Oxyphencyclimine hydrochloride is a Commodity code that captures specific pharmaceutical active ingredients purchased by state and local health and human services agencies, correctional departments, and cooperative purchasing alliances for inclusion in broader pharmacy benefit programs, drug testing operations, and formulary management. Recent state and local solicitations under this code reflect procurement of generic and branded pharmaceutical products as components of larger drug screening, offender testing, and multistate pharmaceutical supply agreements rather than standalone ingredient purchases. State and local issuing bodies soliciting under this code include county community supervision and corrections departments, state health and human services commissions, and regional cooperative purchasing alliances serving multiple state and local government entities across healthcare, public health, and criminal justice administration.

Activity under this code concentrates in Texas and Minnesota, where recent opportunities span offender drug testing services and multistate generic pharmaceutical supply agreements. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for Offender Specimen Collection and Drug Testing Services, due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, encompassing immunoassay screening, LC/MS/MS or GC/MS confirmation, and alternative testing methodologies across two North Texas collection sites with approximately 25,031 annual tests. The Texas Health and Human Services Commission issued RFI No. HHS0017013 in April 2026 soliciting vendor capabilities for direct-to-manufacturer prescription programs to inform future procurement strategy. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products with proposals due March 26, 2026, establishing multiple contracts effective July 1, 2026 for distribution through authorized wholesalers across participating state and local government facilities including Oregon, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance, qualifications, and service capabilities.